OncoTherapy Science, Inc.
JPX: 4564.T0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Tokyo Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Junichi Shimada
- Employees
- 54
- Headquarters
- Kawasaki, Japan
- IPO year
- 2005
- Market cap
- ¥8.2B
- Website
- https://www.oncotherapy.co.jp
Loading 4564…
Loading profile data…Frequently asked questions about 4564
What does OncoTherapy Science, Inc. (4564.T) do?
OncoTherapy Science, Inc. researches and develops anti-cancer medicines and therapies in Japan. Its clinical development product pipeline includes small-molecule drugs, such as OTS167, a maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clin...
Where does 4564.T trade?
OncoTherapy Science, Inc. (4564.T) trades on the Tokyo Stock Exchange.
What sector is 4564.T in?
OncoTherapy Science, Inc. (4564.T) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of OncoTherapy Science, Inc.?
Junichi Shimada is the chief executive officer of OncoTherapy Science, Inc. (4564.T).
Where is OncoTherapy Science, Inc. headquartered?
OncoTherapy Science, Inc. is headquartered in Japan.
Does 4564.T pay a dividend?
OncoTherapy Science, Inc. (4564.T) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 4564.T go public?
OncoTherapy Science, Inc. (4564.T) completed its initial public offering in 2005.